AlphaCentric Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

AlphaCentric Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30,000	Closed	-$1.07M	–	277
2023 Q3	$1.07M	Buy	30,000 +1,500	+5%	+$59.4K	0.61%	57
2023 Q2	$1.31M	Hold	28,500	–	–	0.73%	51
2023 Q1	$1.14M	Buy	28,500 +1,500	+6%	+$64.4K	0.79%	38
2022 Q4	$1.25M	Buy	+27,000	New	+$1.06M	1.24%	22

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

AlphaCentric Advisors's RARE Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2023, closing a stake of 30,000 shares — an estimated $1.07M sold.

AlphaCentric Advisors first reported a position in RARE in Q4 2022 and held it in 4 quarters. The position peaked at $1.31M in Q2 2023. 236 funds tracked by Wall St. Rank hold RARE as of Q4 2023.

AlphaCentric Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 30,000 Ultragenyx Pharmaceutical shares in Q4 2023, an estimated $1.07M.
AlphaCentric Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 4 quarters.
AlphaCentric Advisors's Ultragenyx Pharmaceutical position peaked at $1.31M in Q2 2023.
236 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.